HIV+ve patient is being infused amphotericin B for fungal systemic infection. Which of the following method should be used to manage patient’s iv-cannula and tubing?
**Core Concept**
In patients with HIV/AIDS, especially those on antiretroviral therapy (ART), managing infusions and parenteral therapy is crucial to prevent microbial contamination and subsequent infections. This is particularly relevant when administering antifungal agents like amphotericin B, which has a narrow therapeutic index and requires precise dosing.
**Why the Correct Answer is Right**
The correct method for managing IV cannula and tubing in an HIV-positive patient receiving amphotericin B involves using a closed-system infusion setup with a Y-tubing or a dedicated antiseptic-impregnated catheter to reduce the risk of catheter-related bloodstream infections (CRBSIs). This setup allows for the administration of antibiotics or antifungal agents without exposing the patient to unnecessary microbial contamination. Regular saline flushes are also essential to maintain patency and prevent bacterial growth.
**Why Each Wrong Option is Incorrect**
**Option A:** Using a standard saline flush without a closed-system setup would increase the risk of microbial contamination, making it a less ideal choice.
**Option B:** Reusing IV cannulae or tubing without proper sterilization can lead to CRBSIs and sepsis, particularly in immunocompromised patients like those with HIV/AIDS.
**Option C:** Administering amphotericin B through a standard IV line without antiseptic-impregnated tubing may lead to microbial colonization and subsequent infections.
**Clinical Pearl / High-Yield Fact**
To minimize the risk of CRBSIs and sepsis in HIV-positive patients, always use a closed-system infusion setup with antiseptic-impregnated catheters or dedicated Y-tubing for administering parenteral therapy.
**Correct Answer:** B. Replacing the IV cannula and tubing with a new set every 72-96 hours, or as per hospital protocol, is the recommended practice to prevent CRBSIs and sepsis in immunocompromised patients.